Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Apr 27;25(1):302.
doi: 10.1186/s12876-025-03860-9.

Platelet-to-high-density lipoprotein ratio (PHR) as a predictive biomarker for gastrointestinal cancers: evidence from NHANES

Yan Tong  1 , Xiaojun Lou  2
Affiliations

Platelet-to-high-density lipoprotein ratio (PHR) as a predictive biomarker for gastrointestinal cancers: evidence from NHANES

Yan Tong et al. BMC Gastroenterol. .

Abstract

Background: Gastrointestinal (GI) cancers, including gastric, colorectal, and esophageal cancers, pose a significant global health burden. Despite advancements in diagnostic tools, early detection remains challenging, particularly in low-resource settings. Emerging evidence highlights the platelet-to-high-density lipoprotein ratio (PHR) as a novel biomarker integrating systemic inflammation and lipid metabolism. However, its association with GI cancer risk remains underexplored.

Methods: This study utilized data from the National Health and Nutrition Examination Survey (NHANES) from 2010 to 2018, comprising 19,388 participants, including 230 with GI cancers. PHR was calculated as the ratio of platelet count to high-density lipoprotein cholesterol levels and categorized into quartiles. Weighted logistic regression models, restricted cubic spline analysis, and subgroup analyses were employed to evaluate the association between PHR and GI cancer risk, adjusting for demographic, socioeconomic, lifestyle, and clinical factors.

Results: Elevated PHR was independently associated with an increased risk of GI cancers. Participants in the highest PHR quartile exhibited a significantly higher risk (adjusted OR = 3.09; 95% CI: 2.16-4.43) compared to the lowest quartile. A dose-response relationship was observed, with two critical inflection points at PHR values of 3.2 and 4.5. Subgroup analyses revealed stronger associations among older adults, males, and obese individuals. The findings suggest that PHR may reflect the dynamic balance of systemic inflammation and lipid metabolism, contributing to tumorigenesis.

Conclusion: This study identifies PHR as a promising, cost-effective biomarker for early detection and risk stratification of GI cancers. Its integration into screening programs could improve precision medicine strategies by identifying high-risk individuals for early intervention. Further longitudinal and mechanistic studies are warranted to confirm these findings and explore the underlying biological mechanisms.

Keywords: Cancer screening; Dose-response relationship; Gastrointestinal cancers; Lipid metabolism; NHANES; Platelet-to-high-density lipoprotein ratio (PHR).

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethics approval and consent to participate: This study utilized publicly available, de-identified data from the National Health and Nutrition Examination Survey (NHANES), which is exempt from additional ethical review according to the National Center for Health Statistics (NCHS) Research Ethics Review Board. No ethical approval was required for this study. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Flowchart for study population selection
Fig. 2
Fig. 2
Weighted restricted cubic spline plot of the association between PHR and gastrointestinal cancer risk
Fig. 3
Fig. 3
Forest plot of subgroup analysis and interaction analysis for the association between PHR and gastrointestinal cancer
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Arnold M, Abnet CC, Neale RE, Vignat J, Giovannucci EL, McGlynn KA, Bray F. Global burden of 5 major types of gastrointestinal cancer. Gastroenterology. 2020;159(1):335–e34915. 10.1053/j.gastro.2020.02.068. Epub 2020 Apr 2. PMID: 32247694; PMCID: PMC8630546. - PMC - PubMed
    1. Bordry N, Astaras C, Ongaro M, Goossens N, Frossard JL, Koessler T. Recent advances in gastrointestinal cancers. World J Gastroenterol. 2021;27(28):4493–503. 10.3748/wjg.v27.i28.4493. PMID: 34366620; PMCID: PMC8326255. - PMC - PubMed
    1. Danpanichkul P, Auttapracha T, Sukphutanan B, Ng CH, Wattanachayakul P, Kongarin S, Dutta P, Duangsonk K, Thongpiya J, Muthiah MD, Huang DQ, Lui RN, Seko Y, Takahashi H, Noureddin M, Yang JD, Wallace MB, Wijarnpreecha K. The burden of overweight and obesity-associated gastrointestinal cancers in low and lower-middle-income countries: a global burden of disease 2019 analysis. Am J Gastroenterol. 2024;119(6):1177–80. 10.14309/ajg.0000000000002819. Epub 2024 Apr 22. PMID: 38900306. - PubMed
    1. Lu L, Mullins CS, Schafmayer C, Zeißig S, Linnebacher M. A global assessment of recent trends in gastrointestinal cancer and lifestyle-associated risk factors. Cancer Commun (Lond). 2021;41(11):1137–51. 10.1002/cac2.12220. Epub 2021 Sep 25. PMID: 34563100; PMCID: PMC8626600. - PMC - PubMed
    1. Brown KA, Scherer PE. Update on adipose tissue and cancer. Endocr Rev. 2023;44(6):961–74. 10.1210/endrev/bnad015. PMID: 37260403; PMCID: PMC10638602. - PMC - PubMed

LinkOut - more resources